S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC
OncLive® On Air - Un pódcast de OncLive® On Air
Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.
